8-K: Geron's RYTELO Receives FDA Approval for Lower-Risk MDS Treatment

The FDA has approved Geron's RYTELO (imetelstat) for treating adult patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia.

Summary

• Geron Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO (imetelstat) for the treatment of adult patients with lowto intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.
• This approval is specifically for patients who require four or more red blood cell units over eight weeks and have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs).
• RYTELO is a first-in-class telomerase inhibitor, and its approval is based on results from the IMerge Phase 3 clinical trial.
• The IMerge trial showed significantly higher rates of red blood cell transfusion independence (RBC-TI) with RYTELO compared to placebo, both for at least eight consecutive weeks (39.8% vs 15.0%) and for at least 24 weeks (28.0% vs 3.3%).
• The median duration of RBC-TI was approximately 1 year for 8-week responders and 1.5 years for 24-week responders.
• Patients treated with RYTELO also experienced median increases in hemoglobin of 3.6 g/dL compared to 0.8 g/dL for placebo in an exploratory analysis of 8-week RBC-TI responders.
• The most common Grade 3/4 adverse reactions were neutropenia (72%) and thrombocytopenia (65%), which were generally manageable and short-lived.

Sentiment

Score: 9

Explanation: The document is highly positive due to the FDA approval of a novel treatment, RYTELO, and the strong clinical trial results. The potential for improved patient outcomes and the company's transition to a commercial stage contribute to the high sentiment.

Positives

• RYTELO is the first telomerase inhibitor to be approved by the FDA, representing a new class of treatment for lower-risk MDS.
• The IMerge Phase 3 trial demonstrated statistically significant and clinically meaningful improvements in red blood cell transfusion independence compared to placebo.
• RYTELO showed efficacy across key MDS subgroups, regardless of ring sideroblast status, baseline transfusion burden, and IPSS risk category.
• The safety profile of RYTELO was well-characterized, with cytopenias being generally manageable with dose modifications.
• The treatment has the potential to provide extended and continuous red blood cell transfusion independence, which is a significant unmet need for patients with lower-risk MDS.

Negatives

• The most common Grade 3/4 adverse reactions were neutropenia (72%) and thrombocytopenia (65%), which require careful monitoring and management.
• Serious adverse reactions occurred in 32% of patients who received RYTELO, including sepsis, fracture, cardiac failure, and hemorrhage.
• Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis.
• Infusion-related reactions occurred in 8% of patients, with some being severe.

Risks

• There are risks associated with commercializing RYTELO, including potential delays and challenges related to manufacturing, regulatory approvals, and market adoption.
• The company may need to raise additional capital to support the commercialization of RYTELO and further development of imetelstat.
• There are risks related to the safety and efficacy of imetelstat, and future results may cause the benefit-risk profile to become unacceptable.
• The company faces risks related to manufacturing and supplying sufficient quantities of imetelstat.
• The timing for the interim and final analyses of the IMpactMF trial may vary depending on actual enrollment and death rates.

Future Outlook

Geron aims to ensure broad access to RYTELO for eligible patients and is also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. The company believes that imetelstat has the potential to demonstrate disease-modifying activity in patients.

Management Comments

• John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, stated that the approval of RYTELO is a testament to the power of their science and the passion of their people to innovate in the field of blood cancer.
• Rami Komrokji, MD, Vice Chair, Malignant Hematology Department, Moffitt Cancer Center, noted that the approval of RYTELO is potentially practice-changing for hematologists treating patients with lower-risk MDS and anemia who are transfusion dependent.

Industry Context

This announcement is significant as it introduces a new class of treatment, a telomerase inhibitor, for lower-risk MDS, an area with high unmet need. Current treatment options are limited, and RYTELO offers a new approach to managing the disease, potentially improving patient outcomes and quality of life. This approval could set a new standard of care for this patient population.

Comparison to Industry Standards

• Current treatments for lower-risk MDS with transfusion-dependent anemia often involve erythropoiesis-stimulating agents (ESAs), which many patients eventually become resistant to or are ineligible for.
• The IMerge Phase 3 trial results for RYTELO show a significant improvement in red blood cell transfusion independence compared to placebo, which is a key goal in managing this condition.
• While other treatments like lenalidomide and hypomethylating agents are used in MDS, RYTELO's mechanism of action as a telomerase inhibitor is novel and targets a different pathway.
• Companies like Celgene (now part of Bristol Myers Squibb) with Revlimid (lenalidomide) and Astex Pharmaceuticals with Inqovi (decitabine and cedazuridine) offer treatments for MDS, but RYTELO's unique approach could position it as a valuable alternative, especially for patients who have failed or are ineligible for other therapies.
• The 28% 24-week RBC-TI rate for RYTELO is a significant improvement over the 3.3% rate for placebo, and this level of efficacy is not commonly seen with existing treatments in this patient population.

Stakeholder Impact

• Shareholders will likely view the FDA approval positively, potentially leading to an increase in stock value.
• Patients with lower-risk MDS and transfusion-dependent anemia will have a new treatment option that could improve their quality of life and reduce their reliance on transfusions.
• Healthcare providers will have a new tool for managing this challenging condition.
• Employees of Geron will be impacted by the company's transition to a commercial stage and the potential for growth.

Next Steps

• Geron will focus on commercializing RYTELO for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
• The company will continue the pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF).
• Geron will also continue studies of imetelstat in other hematologic malignancies.
• The company will ensure broad access to RYTELO through its REACH4RYTELO Patient Support Program.

Key Dates

Keywords

RYTELO, imetelstat, MDS, myelodysplastic syndromes, anemia, transfusion-dependent, telomerase inhibitor, FDA approval, IMerge Phase 3, red blood cell transfusion independence, RBC-TI, neutropenia, thrombocytopenia